Recent 8-K filings for IMMX
Highest-materiality recent filing
Immix Biopharma reports 75% CR rate in Phase 2 NXC-201 for AL amyloidosis, BLA plan 2026
- NXC-201 achieved 75% complete response (15/20) by independent review committee in relapsed/refractory AL amyloidosis.
- MRD negativity in 4 of 5 pending patients suggests future CR rate could reach 95%.
-
Immix Biopharma prices $150M public offering of 16.8M shares at $8.94
Gross proceeds $150M; net proceeds ~$140.65M after discounts and expenses.
-
Immix Biopharma reports 95% CR rate in NEXICART-2; all MRD-negative patients convert to CR
All four MRD-negative relapsed/refractory AL Amyloidosis patients from ASH 2025 have converted to complete response (CR).
-
Immix Biopharma completes NEXICART-2 enrollment; topline results Q3 2026
Enrollment complete for 40-patient BLA-enabling Phase 2 trial NEXICART-2 (NCT06097832) in relapsed/refractory AL Amyloidosis.
-
Immix Biopharma reports 75% CR rate in Phase 2 NXC-201 for AL amyloidosis, BLA plan 2026
NXC-201 achieved 75% complete response (15/20) by independent review committee in relapsed/refractory AL amyloidosis.
-
Immix Biopharma raises ~$93.7M net via 19.1M share and warrant offering at $5.10
19,117,646 shares at $5.10/share and 490,196 pre-funded warrants at $5.09/warrant in underwritten offering.
-
Immix Biopharma raises $9.1M in PIPE; Nancy Chang appointed to board
Sold 3,831,216 shares at $2.37/share and warrants for 2,873,417 shares at $2.00/share.
-
Immix Biopharma subsidiary Nexcella awarded $8M CIRM grant for NXC-201 AL Amyloidosis trial
$8 million CLIN2 grant from California Institute for Regenerative Medicine to support NXC-201 CAR-T therapy for relapsed/refractory AL Amyloidosis.
-
Immix Biopharma completes short-form merger of majority-owned subsidiary Nexcella
On May 20, 2024, Immix merged its >95%-owned subsidiary Nexcella into itself; Nexcella ceased to exist.
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event other_material